CLTX-CAR T cells(Chimeric Therapeutics)

SYDNEY, Australia and NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Chimeric Therapies, Inc. (ASX: CHM) (“Chimeric Therapeutics”, “Chimeric” or the “Company”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is please to announce that Jennifer Chow, Chief Executive Officer and Managing Director, will present at the Biotechnology Innovation Organization (BIO) International Convention, taking place June 5-8, 2023 at the Boston Convention and Exhibition Center in Boston, Massachusetts. BIO Presentation (in-person) Details: Date: Monday, June 5, 2023 Presentation Time: 4:15 p.m. ET Location: Room 104B Chimeric’s Management will also be participating in partnering meetings to review its pipeline of unique and proprietary cell therapy programs. Attendees can schedule a meeting with the Team by clicking here. ABOUT CHIMERIC THERAPEUTICS: Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression. To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies. Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2023. CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Initial positive data from the investigator-initiated phase 1A trial has been presented on patients treated in the first two dose levels of the trial. CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours. CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets. Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper. CONTACT: Investors Jennifer Chow Paul Hopper Chief Executive Officer and Manager Director Executive Chairman Chimeric Therapeutics Chimeric Therapeutics T: 1 908 723 8387 T: +61 406 671 515 E: jchow@chimerictherapeutics.com E: paulhopper@lifescienceportfolio.com W: Media Matthew Wright NWR Communications P: +61 451 896 420 E: matt@mwrcommunications.com.au Forward-Looking Statements Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law. This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.